AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for 2'-5'-oligoadenylate synthase-like protein

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our high-tech, dedicated method is applied to construct targeted libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q15646

UPID:

OASL_HUMAN

Alternative names:

2'-5'-OAS-related protein; 59 kDa 2'-5'-oligoadenylate synthase-like protein; Thyroid receptor-interacting protein 14; p59 OASL

Alternative UPACC:

Q15646; B2RAZ2; I1YDD2; O75686; Q17R95; Q9Y6K6; Q9Y6K7

Background:

The 2'-5'-oligoadenylate synthase-like protein, known by alternative names such as 2'-5'-OAS-related protein and p59 OASL, plays a crucial role in the innate immune response. Despite lacking 2'-5'-OAS activity, it binds double-stranded RNA and exhibits antiviral activity against viruses like EMCV and HCV through an alternative pathway independent of RNase L.

Therapeutic significance:

Understanding the role of 2'-5'-oligoadenylate synthase-like protein could open doors to potential therapeutic strategies. Its unique mechanism of action in antiviral defense highlights its potential as a target for developing novel antiviral therapies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.